...
首页> 外文期刊>Journal of experimental & clinical cancer research : >The CD112R/CD112 axis: a breakthrough in cancer immunotherapy
【24h】

The CD112R/CD112 axis: a breakthrough in cancer immunotherapy

机译:CD112R / CD112轴:癌症免疫疗法的突破

获取原文
           

摘要

The recent discovery of immune checkpoint inhibitors is a significant milestone in cancer immunotherapy research. However, some patients with primary or adaptive drug resistance might not benefit from the overall therapeutic potential of immunotherapy in oncology. Thus, it is becoming increasingly critical for oncologists to explore the availability of new immune checkpoint inhibitors. An emerging co-inhibitory receptor, CD112R (also called PVRIG), is most commonly expressed on natural killer (NK) and T cells. It binds to its ligand (CD112 or PVRL2/nectin-2) and inhibits the strength with which T cells and NK cells respond to cancer. Therefore, CD112R is being presented as a new immune checkpoint inhibitor with high potential in cancer immunotherapy. CD112 is easily detectable on antigen-presenting or tumor cells, and its high level of expression has been linked with tumor progression and poor outcomes in most cancer patients. This review explores the molecular and functional relationship between CD112R, TIGIT, CD96, and CD226 in T cell responses. In addition, this review comprehensively discusses the recent developments of CD112R/CD112 immune checkpoints in cancer immunotherapy and prognosis.
机译:最近发现免疫检查点抑制剂是癌症免疫治疗研究中的重要里程碑。然而,一些患有初级或适应性耐药性的患者可能不会受益于肿瘤学中免疫疗法的总体治疗潜力。因此,对于肿瘤医学家来说,探讨新免疫检查点抑制剂的可用性变得越来越关键。新兴共同抑制受体CD112R(也称为PVRIG),最常在天然杀伤剂(NK)和T细胞上表达。它与其配体(CD112或PVRL2 / Nectin-2结合)并抑制T细胞和NK细胞对癌症的强度。因此,CD112R正在呈现为具有高癌症免疫疗法的新免疫检查点抑制剂。在抗原呈递或肿瘤细胞上易于检测CD112,其高水平的表达与大多数癌症患者的肿瘤进展和差的结果有关。该综述探讨了T细胞应答中CD112R,TIGIT,CD96和CD226之间的分子和功能关系。此外,本综述讨论了癌症免疫治疗和预后CD112R / CD112免疫检查点最近的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号